Advertisement
Findings call for revisiting readmission prevention strategies
Nearly 40 percent of readmissions in the three months following myocardial infarction (MI) occurred within the first 15 days, and these early readmissions stemmed chiefly from cardiovascular causes. Those findings, from a new large single-center analysis at Cleveland Clinic, argue for initiating readmission prevention strategies well before MI patients are discharged, the researchers note.
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
“Our analysis suggests that the factors leading to readmission after MI are often likely to be embedded within the index hospitalization,” says Umesh N. Khot, MD, lead author of the study, published as a letter in the August 2017 issue of the Journal of the American College of Cardiology. “Efforts to prevent readmission need to account for the changes in risk over time that we observed, and these efforts should start early during the index admission.”
He and colleagues undertook their analysis to better define the risk of readmission after MI over time and by cause of readmission. “As reimbursement continues to shift toward bundled payments, understanding when and why patients are at highest risk of readmission is key to providing quality care and managing costs,” explains Dr. Khot, Vice Chairman of Cardiovascular Medicine at Cleveland Clinic.
They retrospectively identified all patients discharged from Cleveland Clinic’s main campus hospital with a principal diagnosis of MI from April 2008 to June 2012. The institutional billing system was used to identify all readmissions to the Cleveland Clinic health system within 90 days of the index MI. In all cases the primary cause of readmission was assigned to one of four categories:
Among the 3,069 patients discharged after an index MI, 494 readmissions occurred within three months of discharge. Key observations included the following:
Advertisement
“We found that both the risk and primary cause of readmission changed markedly over time,” says co-author Michael J. Johnson, MD, an interventional cardiology fellow at Cleveland Clinic. “These findings contrast with prior studies suggesting that the causes of post-MI readmission did not vary substantially over time.”
He notes that this is one of the first investigations to evaluate the risk and cause of readmission in the second and third months following discharge after MI. The study showed that readmission risk during this time was substantially lower than in the first month after discharge and remained relatively constant.
While acknowledging the limitations of a single-center retrospective study like this, including the inability to capture readmissions outside the Cleveland Clinic health system, Dr. Khot says this investigation offers several notable takeaways.
“The risk of post-MI readmission was highest right after discharge — especially for MI-related and other CV-related causes — and plummeted by nearly half within 15 days after discharge,” he observes. “This suggests readmission is often apt to be linked to aspects of the initial hospitalization. So strategies to curb readmissions should start on the day of the admission, not the day of discharge.”
He adds that the finding of variance in readmission risk over time and by cause might call for “a more nuanced approach” to preventing readmissions and improving the quality of MI care. “Factoring in such nuances may make sense both for hospitals and for the payers that hold hospitals accountable for post-MI readmissions,” Dr. Khot concludes.
Advertisement
Advertisement
Study authors urge reevaluation of the sweetener’s safety designation by food regulators
Surprise findings argue for caution about testosterone use in men at risk for fracture
Findings support emphasis on markers of frailty related to, but not dependent on, age
Large database study reveals lingering health consequences of decades-old discrimination
Additional analyses of the two trials presented at 2023 ESC Congress
Prospective SPIRIT-HCM trial demonstrates broad gains over 12-month follow-up
An ACC committee issues recommendations to accelerate sluggish progress
Review of our recent experience shows it’s still a safe option